Search results
Your search for TFRC returned no results
Showing 1501 to 1550 of 2486 results for term
Showing 1501 to 1550 of 2486 results for term
This quality standard covers diagnosing and managing common types of headache in adults and young people (aged 12 and over). It includes tension-type headache, migraine, cluster headache and medication overuse headache. It describes high-quality care in priority areas for improvement.
View quality statements for QS42Show all sections
Sections for QS42
- Quality statements
- Quality statement 1: Classification of headache type
- Quality statement 2: Preventing medication overuse headache
- Quality statement 3: Imaging
- Quality statement 4: Combined treatment for migraine
- Quality statement 5 (placeholder): Raising public and professional awareness
- Update information
- About this quality standard
This quality standard covers diagnosing and managing Lyme disease in people of all ages. It also includes raising public awareness about prevention. It describes high-quality care in priority areas for improvement.
Ectopic pregnancy and miscarriage: diagnosis and initial management (NG126)
This guideline covers diagnosing and managing ectopic pregnancy and miscarriage in women with complications, such as pain and bleeding, in early pregnancy (that is, up to 13 completed weeks of pregnancy). It aims to improve how early pregnancy loss is diagnosed, and the support women are given, to limit the psychological impact of their loss.
Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)
Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)
Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) caused by neurological conditions in adults.
Omalizumab for previously treated chronic spontaneous urticaria (TA339)
Evidence-based recommendations on omalizumab (Xolair) for treating severe chronic spontaneous urticaria in people of 12 and over.
Evidence-based recommendations on the Pipeline Flex embolisation device with Shield Technology for the treatment of complex intracranial aneurysms.
Endoscopic full thickness removal of non-lifting colonic polyps (HTG439)
Evidence-based recommendations on endoscopic full thickness removal of non-lifting colonic polyps. This involves using a special device to remove the polyp and seal the bowel wall closed afterwards.
View recommendations for HTG439Show all sections
This guideline covers improving oral health by developing and implementing a strategy that meets the needs of people in the local community. It aims to promote and protect people’s oral health by improving their diet and oral hygiene, and by encouraging them to visit the dentist regularly.
Differential target multiplexed spinal cord stimulation for chronic lower back and leg pain (MIB305)
NICE has developed a medtech innovation briefing (MIB) on differential target multiplexed spinal cord stimulation for chronic lower back and leg pain .
C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)
Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treating and preventing deep vein thrombosis and pulmonary embolism in adults.
NICE has developed a medtech innovation briefing (MIB) on ADXBLADDER for detecting bladder cancer .
This quality standard covers treating and managing psychosis and schizophrenia in adults (aged 18 and over) in primary, secondary and community care. It also includes support for the families and carers of people with psychosis or schizophrenia. It describes high-quality care in priority areas for improvement.
View quality statements for QS80Show all sections
Sections for QS80
- Quality statements
- Quality statement 1: Referral to early intervention in psychosis services
- Quality statement 2: Cognitive behavioural therapy
- Quality statement 3: Family intervention
- Quality statement 4: Treatment with clozapine
- Quality statement 5: Supported employment programmes
- Quality statement 6: Assessing physical health
- Quality statement 7: Promoting healthy eating, physical activity and smoking cessation
This quality standard covers preventing, assessing, diagnosing and managing skin cancer (melanoma and non-melanoma skin cancer). It describes high-quality care in priority areas for improvement.
View quality statements for QS130Show all sections
Sections for QS130
Suspected neurological conditions: recognition and referral (QS198)
This quality standard covers assessing and referring children (under 16) and adults (16 and over) who have symptoms or signs associated with neurological conditions. It describes high-quality care in priority areas for improvement.
View quality statements for QS198Show all sections
Sections for QS198
- Quality statements
- Quality statement 1: Headaches and 'red flag' symptoms in children
- Quality statement 2: Head size and shape in children
- Quality statement 3: Suspected dystonia in adults
- Quality statement 4: Hallpike manoeuvre for adults
- Quality statement 5: Functional neurological disorders in adults
- Quality statement 6: Individualised care for adults
- About this quality standard
Cardiovascular risk assessment and lipid modification (QS100)
This quality standard covers identifying and assessing cardiovascular risk in adults without cardiovascular disease, and treatment to prevent primary and secondary cardiovascular disease. It describes high-quality care in priority areas for improvement.
View quality statements for QS100Show all sections
Sections for QS100
- Quality statements
- Quality statement 1: Identifying adults who are likely to be at high risk
- Quality statement 2: Diet and lifestyle advice for primary prevention
- Quality statement 3: Lipid-lowering treatment for primary prevention
- Quality statement 4: Assessing response to lipid-lowering treatment
- Quality statement 5: Secondary prevention of cardiovascular disease
- Update information
- About this quality standard
Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)
Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making
This quality standard covers providing and organising services for people with sarcoma. It includes pathways for referral and diagnosis, treatment and support for adults, young people and children with sarcoma. It describes high-quality care in priority areas for improvement.
View quality statements for QS78Show all sections
Sections for QS78
- Quality statements
- Quality statement 1: Diagnostic pathways
- Quality statement 2: Multidisciplinary teams for sarcoma
- Quality statement 3: Publishing information about areas of expertise
- Quality statement 4: Retroperitoneal sarcoma
- Quality statement 5: Surgical skills
- Quality statement 6: Key workers
- Update information
This quality standard covers managing idiopathic pulmonary fibrosis (gradual scarring of the lungs) in adults. It includes diagnosis by a multidisciplinary team, managing symptoms and palliative care. It describes high-quality care in priority areas for improvement.
View quality statements for QS79Show all sections
Sections for QS79
- Quality statements
- Quality statement 1: Diagnosis of idiopathic pulmonary fibrosis
- Quality statement 2: Access to a specialist nurse
- Quality statement 3: Assessment for oxygen therapy
- Quality statement 4: Pulmonary rehabilitation
- Quality statement 5: Palliative care
- Update information
- About this quality standard
This guideline covers decision-making in people 16 years and over who may lack capacity now or in the future. It aims to help health and social care practitioners support people to make their own decisions where they have the capacity to do so. It also helps practitioners to keep people who lack capacity at the centre of the decision-making process.
NICE has developed a medtech innovation briefing (MIB) on Accuro for guiding epidural or spinal anaesthesia .
This quality standard covers diagnosing and managing endometriosis in women and people, including those aged 17 and under. It describes high-quality care in priority areas for improvement.
This quality standard covers identifying, assessing and treating attachment difficulties in children and young people (under 18). It focuses on children and young people at high risk of going into care, looked after by local authorities in foster homes, in special guardianship, adopted from care, and those in residential settings and other accommodation. It describes high-quality care in priority areas for improvement.
Evidence-based recommendations on insertion of customised titanium implants, with soft tissue cover, for orofacial reconstruction. This involves inserting titanium implants to replace broken bones in the face as part of orofacial reconstruction.
View recommendations for HTG307Show all sections
Sections for HTG307
NICE has developed a medtech innovation briefing (MIB) on Optilume for anterior urethral strictures .
Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people aged 3 and older who have had a stem cell transplant or at least 2 previous therapies.
dorsal rhizotomy suggests that the procedure results in some short- and medium-term improvements in motor function. The effects reported...
Gilteritinib for treating relapsed or refractory acute myeloid leukaemia (TA642)
Evidence-based recommendations on gilteritinib (Xospata) for relapsed or refractory FLT3-mutation-positive acute myeloid leukaemia in adults.
intermediate care:- How effective and cost effective are different approaches, in terms of duration and intensity, to providing...
Carnation Ambulatory Monitor for ambulatory detection of cardiac arrythmias (MIB276)
NICE has developed a medtech innovation briefing (MIB) on Carnation Ambulatory Monitor for ambulatory detection of cardiac arrythmias .
RespiraSense for continuously monitoring respiratory rate (MIB299)
NICE has developed a medtech innovation briefing (MIB) on RespiraSense for continuously monitoring respiratory rate .
SecurAcath for securing cerebrospinal fluid catheters (MIB107)
NICE has developed a medtech innovation briefing (MIB) on SecurAcath for securing cerebrospinal fluid catheters .
Evidence-based recommendations on gefitinib (Iressa) for untreated locally advanced or metastatic non-small-cell lung cancer in adults.
Evidence-based recommendations on atezolizumab (Tecentriq) with nab-paclitaxel for triple-negative, unresectable, PD-L1-positive, locally advanced or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.
Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.
Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)
Evidence-based recommendations on machine perfusion systems and cold static storage of kidneys from deceased donors.
This quality standard covers the mental wellbeing of older people (aged 65 and over) receiving care in care homes (including residential and nursing accommodation, day care and respite care). It focuses on support for people to improve their mental wellbeing so that they can stay as well and independent as possible. It describes high-quality care in priority areas for improvement.
View quality statements for QS50Show all sections
Sections for QS50
- Quality statements
- Quality statement 1: Participation in meaningful activity
- Quality statement 2: Personal identity
- Quality statement 3: Recognition of mental health conditions
- Quality statement 4: Recognition of sensory impairment
- Quality statement 5: Recognition of physical problems
- Quality statement 6: Access to healthcare services
- Update information
This quality standard covers identifying and supporting adults and young people (aged 10 and over) who may have an alcohol-use disorder and caring for people with alcohol-related health problems, as well as support for their families and carers. It describes high-quality care in priority areas for improvement.
View quality statements for QS11Show all sections
Sections for QS11
- Quality statements
- Quality statement 1: Use of validated alcohol questionnaires
- Quality statement 2: Community support networks and self-help groups
- Quality statement 3: Triage assessment in specialist alcohol services
- Quality statement 4: Acute alcohol withdrawal
- Quality statement 5: Interventions to prevent relapse after unplanned withdrawal from alcohol in hospital
- Update information
- About this quality standard
This quality standard covers diagnosing, assessing and managing cerebral palsy in children and young people under 25. It describes high-quality care in priority areas for improvement.
View quality statements for QS162Show all sections
Sections for QS162
- Quality statements
- Quality statement 1: Follow-up for children with major risk factors for cerebral palsy
- Quality statement 2: Referral for children with delayed motor milestones
- Quality statement 3: Information for parents and carers of children and young people with cerebral palsy
- Quality statement 4: Personal folders for children and young people with cerebral palsy
- About this quality standard
This quality standard covers preventing and identifying alcohol problems in the community. It includes policy and practice approaches to prevent harmful alcohol use in adults, young people and children. It is particularly relevant to local authorities, the police, and schools and colleges. It describes high-quality care in priority areas for improvement.
View quality statements for QS83Show all sections
Sections for QS83
This quality standard covers diagnosing and managing depression in children and young people (aged 5 to 18). It describes high-quality care in priority areas for improvement.
View quality statements for QS48Show all sections
Sections for QS48
- Quality statements
- Quality statement 1: Confirming and recording a diagnosis
- Quality statement 2: Information appropriate to age
- Quality statement 3: Suspected severe depression and at high risk of suicide
- Quality statement 4: Suspected severe depression without high risk of suicide
- Quality statement 5: Monitoring progress
- Update information
- About this quality standard
Targeted muscle reinnervation for managing limb amputation pain (HTG750)
Evidence-based recommendations on targeted muscle reinnervation for managing limb amputation pain. This involves attaching nerves that were cut during limb amputation to other nerves in nearby muscles.
Evidence-based recommendations on balloon disimpaction of the baby’s head at emergency caesarean during the second stage of labour. This involves inserting a silicone balloon into the vagina and inflating to lift the baby’s head before starting the caesarean.
Parkinson's disease, as opposed to after motor symptom onset, confer benefits in terms of delaying symptom onset and/or reducing...
End of life care for infants, children and young people (QS160)
This quality standard covers end of life care for infants, children and young people (from birth to 18 years) who have a life-limiting condition. Life-limiting conditions are those that are expected to result in an early death for the person. It also covers support for family members and carers. It describes high-quality care in priority areas for improvement.
View quality statements for QS160Show all sections
Sections for QS160
- Quality statements
- Quality statement 1: Advance care plan
- Quality statement 2: Named medical specialist
- Quality statement 3: Emotional and psychological support
- Quality statement 4: Specialist paediatric palliative care team
- Quality statement 5: Support for grief and loss for parents or carers
- Quality statement 6: Care at home
- About this quality standard
cost burden for the NHS in terms of critical care admissions, prolonged inpatient stays or the potential need for long-term...
Chronic wounds: advanced wound dressings and antimicrobial dressings (ESMPB2)
Summary of the evidence on advanced wound dressings and antimicrobial dressings for managing chronic wounds to inform local NHS planning and decision-making
Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia (TA119)
Evidence-based recommendations on fludarabine monotherapy for untreated chronic lymphocytic leukaemia in adults.
Kendall DL for ECG monitoring in people having cardiac surgery (MIB177)
NICE has developed a medtech innovation briefing (MIB) on Kendall DL for ECG monitoring in people having cardiac surgery .